Drug intelligence / Profile preview

Almasilate

Development stage: Unknown
Lead developer: Elementis
Modality: Small Molecules
Administration: Oral

Overview

Almasilate is a buffering antacid used for the symptomatic treatment of conditions requiring neutralization of excess stomach acid, such as peptic ulcers, duodenal ulcers, heartburn, and dyspepsia. It is a crystalline polyhydrate composed of aluminium/magnesium silicate. Its mechanism of action involves binding hydrogen ions within its polymer matrix in the stomach to neutralize gastric acid. Almasilate acts locally in the gastrointestinal tract and does not significantly differ in efficacy from other conventional antacids. It is primarily available in certain parts of Europe and Asia and may be found as a single agent or combined with other antacids like calcium carbonate or sodium bicarbonate[1][2][3][5][6].

Brand names: MegalacMalinalSimagel
Other names: almasilateDianeusineAlmasilatum

Beyond the preview

Go deeper on Almasilate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Almasilate.

Explore the full profile